Navigation Links
Prostate Hormone Therapy May Up Heart Risks
Date:12/7/2009

The study she led looked at its effects on about 37,000 men treated for prostate cancer at Veterans Affairs hospitals.

Surgical removal of the testes was associated with a 40 percent increased risk for heart disease and a more than doubled risk for heart attack. Use of multiple hormone-blocking agents was associated with a 27 percent increased risk for heart disease.

The greatest risk was found for drugs that target gonadotropin-releasing hormone: 159.4 cases of diabetes per 1,000 person-years, compared with 87.5 for men who did not have androgen deprivation therapy, as well as a 35 percent increased risk for sudden cardiac death, a comparable increase in heart attack risk and a 22 percent increased risk for stroke.

Observational studies, which include all people with a condition, can never conclusively prove cause and effect, Keating acknowledged, because "the thing we can't account for is whether people who are on a treatment are different from those who aren't." But detailed evidence about the potential dangers of androgen deprivation therapy has not emerged from the more rigorous controlled trials that have been done "because they have looked only at cardiovascular deaths, and most patients who have heart attacks do not die of those heart attacks," she said.

Dr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that "the point of this paper is to help physicians understand that long-term use of this therapy carries consequences." Albertsen wrote an accompanying editorial in the journal.

Anti-hormone therapy was developed to treat the pain and other problems of advanced prostate cancer, Albertsen said, and so it was generally used for only three to five years.

"Now, many more men are being started on androgen deprivation therapy long before there are any symptoms of prostate cancer so they may be on it for up to 15 years," he said. "We are beginning to
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
2. PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients
3. Tulane Cancer Center to begin novel clinical trial for late-stage prostate cancer drug
4. Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds
5. Routine evaluation of prostate size not as effective in cancer screening, Mayo study finds
6. New finding suggests prostate biopsy is not always necessary
7. Does race, income predict prostate cancer outcome?
8. Chemo-radiation before prostate removal may prevent cancer recurrence
9. Blood vessels might predict prostate cancer behavior
10. Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer Patients
11. Adding Proton Therapy Boost to X-Ray Radiation Therapy Reduces Prostate Cancer Recurrences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her ... the leading network of doctors working on a lien basis. Dr. Lim had ... , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain herself ...
(Date:7/6/2015)... ... 06, 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a ... at a CAGR of over 3.2 percent in the years to come to hit ... mainly spurred by an anticipated launch of a number of promising pipeline candidates and ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... in southern California, has partnered with Woodbridge Walk-In Urgent Care to offer on-site ... and other serious medical conditions. Screenings are affordable and accurate and run about ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... ... CA area, Carlson & Associates has once again teamed up with Family Emergency ... homeless families to move toward self-sufficiency. FESCO was created especially to provide emergency ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School ... funds to support a three-year effort to reduce rates of diabetes and cardiovascular ... in partnership with the Morehouse School of Medicine’s Prevention Research Center and the ...
Breaking Medicine News(10 mins):Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2
... suffer from musculoskeletal injuries and conditionsLAS VEGAS, Feb. 25 ... and conditions affect our quality of life every day. ... Surgeons, (AAOS) 2009 multimedia Public Service Advertising Campaign is ... scoliosis and preventing injuries in female athletes, knees. ...
... Study finds many children at risk for foot deformity due ... children are wearing shoes that are too small, according to ... of the American Academy of Orthopaedic Surgeons ( ... at high risk for developing serious foot deformities.The study, which ...
... Molecular Oncology (MOLONC) ( http://www.elsevier.com/locate/molonc ), published ... European Biochemical Societies (FEBS), has been accepted by ... Science Citation Index Expanded (SciSearch), Biosis Previews and ... times a year from January 1, 2009) highlights ...
... EAST RUTHERFORD, N.J., Feb. 25 CCA Industries, Inc. ... fiscal year ended November 30, 2008 were $57,457,946, net ... were $0.20. Revenues for the prior year were ... per share were $0.78. Revenues for the fourth ...
... University of Texas M. D. Anderson ... Gamma Knife (R) Perfexion(TM), an advanced ... or more lesions in the head in a ... http://www.newscom.com/cgi-bin/prnh/20090225/CL74742 )"Leksell Gamma Knife Perfexion suits our ...
... Feb. 20 CUREXO Technology Corporation, pioneer in ... products for orthopaedic applications, which is focused on ... has submitted a premarket notification 510(k) application to ... market clearance in the U.S. for use of ...
Cached Medicine News:Health News:The Most Breaking News in the Joint 2Health News:The Most Breaking News in the Joint 3Health News:The Most Breaking News in the Joint 4Health News:If the Shoe Fits...or Does It? 2Health News:If the Shoe Fits...or Does It? 3Health News:Molecular Oncology accepted into Thomson Reuters index 2Health News:CCA Industries, Inc Announces Year End Results 2Health News:CCA Industries, Inc Announces Year End Results 3Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application 2
(Date:7/6/2015)... June 29, 2015 Research ... the "Pharmaceutical Grade Sodium Chloride Market by Applications, ... report to their offering. The pharmaceutical ... CAGR of 6.9% between 2014 and 2019 in terms ... 690 KT by 2019. The report on ...
(Date:7/6/2015)... 6, 2015 Moerae Matrix, a clinical ... that target inflammation and fibrosis, today announced the ... as Chief Medical Officer. Dr. ... and programs, which include a pipeline of therapies ... conditions.  Bill is an accomplished strategist and scientist ...
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
... N.C. , June 21 Gentris Corporation ... pharmacogenomics, announced today that Rick Williams has ... member of the Board of Directors.  In his role ... company,s scientific leadership continues to provide biotechnology and pharmaceutical ...
... LONDON , June 21 Thomson Reuters announced ... innovative resource designed to change the way biotechnology, pharmaceutical and academic ... , , ... available free to all organizations with drugs in development. It enables ...
Cached Medicine Technology:Gentris Corporation Names New Chief Executive Officer 2Gentris Corporation Names New Chief Executive Officer 3Gentris Corporation Names New Chief Executive Officer 4Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3
... The optomap is the companys core product. ... used in primary level eye care for the ... It is available on a pay-per-patient examination basis ... with a digital wide-field of view of the ...
... Cardiac Digital Camera is a state-of-the-art, office-based nuclear ... and provides full sized fields of view. ... you need a flexible system that can work ... how the Pulse reduces the costs of adding ...
... same cryoconsole and platform technology as Freezor ... veins. Arctic Circler is an ablation tool ... that rely on medication., ,With its ... the ability to create curvilinear lesions rapidly ...
... Coil is intended for: embolization of those ... their location, or the patient's general medical ... team to be a) very high risk ... b) inoperable.,The GDC is also intended for ...
Medicine Products: